The University of Southampton
University of Southampton Institutional Repository

Production of the potent neutrophil chemokine, growth-related protein α (GROα), is not elevated in cystic fibrosis children

Production of the potent neutrophil chemokine, growth-related protein α (GROα), is not elevated in cystic fibrosis children
Production of the potent neutrophil chemokine, growth-related protein α (GROα), is not elevated in cystic fibrosis children

Progressive neutrophil-mediated lung damage causes much of the morbidity and mortality in cystic fibrosis (CF). Neutrophil chemoattractants implicated in CF include interleukin (IL-)8, tumour necrosis factor (TNFα) and leukotriene (LT)B4, but growth-related protein α (GROα), a highly potent neutrophil chemokine, has not been investigated. Atopic status has been considered to contribute to the marked heterogeneity of pulmonary disease in CF. We hypothesized that GROα may be produced in biologically-significant amounts in the CF lung, and that enhanced production of GROα, IL-8 or LTB4 may contribute to the poorer lung function seen in atopic CF patients compared to non-atopic CF patients. GROα, IL-8 and LTB4 levels in the sputum of atopic and non-atopic CF patients were assessed by immunoassays, and GROα and IL-8 levels were also assessed in the plasma of CF patients and normal controls. As expected, there were high levels of IL-8 and LTB4 in most CF sputum samples, and IL-8 levels were higher in CF plasma than in control plasma (P = 0.02). In contrast, GROα was undetectable (< 5 pg ml-1) in the sputum of 21 out of 25 CF patients, with low levels (range 144-825 pg ml-(1)) in the remainder, and median levels of GROα in CF plasma (33 pg ml-1, n = 24) were not significantly different from controls (34 pg ml-1, n = 25). Lung function [forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC)] was significantly poorer in atopic CF compared to non-atopic CF patients (P < 0.02), but sputum levels of GROα, IL-8 and LTB4 were not different between the subgroups. Our results suggest that unlike LTB4 and IL-8, GROα does not contribute to neutrophilic inflammation in the CF lung, and other factors must determine the impaired lung function observed in atopic CF patients. These results may have important implications in the development of chemokine receptor antagonists as novel anti-inflammatory agents in CF. (C) 2000 HARCOURT PUBLISHERS LTD.

Atopy, Chemokine, Cystic fibrosis, GROα
0954-6111
106-111
Wyatt, H. A.
538cf722-59a1-4ea0-a781-8741fef05883
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Balfour-Lynn, I. M.
707ae8d2-6d2c-4bae-ba1d-703c491b96ee
Price, J. F.
eec24b6e-9f4e-4549-a360-3d3560970e0e
Wyatt, H. A.
538cf722-59a1-4ea0-a781-8741fef05883
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Balfour-Lynn, I. M.
707ae8d2-6d2c-4bae-ba1d-703c491b96ee
Price, J. F.
eec24b6e-9f4e-4549-a360-3d3560970e0e

Wyatt, H. A., Sampson, A. P., Balfour-Lynn, I. M. and Price, J. F. (2000) Production of the potent neutrophil chemokine, growth-related protein α (GROα), is not elevated in cystic fibrosis children. Respiratory Medicine, 94 (2), 106-111. (doi:10.1053/rmed.1999.0725).

Record type: Article

Abstract

Progressive neutrophil-mediated lung damage causes much of the morbidity and mortality in cystic fibrosis (CF). Neutrophil chemoattractants implicated in CF include interleukin (IL-)8, tumour necrosis factor (TNFα) and leukotriene (LT)B4, but growth-related protein α (GROα), a highly potent neutrophil chemokine, has not been investigated. Atopic status has been considered to contribute to the marked heterogeneity of pulmonary disease in CF. We hypothesized that GROα may be produced in biologically-significant amounts in the CF lung, and that enhanced production of GROα, IL-8 or LTB4 may contribute to the poorer lung function seen in atopic CF patients compared to non-atopic CF patients. GROα, IL-8 and LTB4 levels in the sputum of atopic and non-atopic CF patients were assessed by immunoassays, and GROα and IL-8 levels were also assessed in the plasma of CF patients and normal controls. As expected, there were high levels of IL-8 and LTB4 in most CF sputum samples, and IL-8 levels were higher in CF plasma than in control plasma (P = 0.02). In contrast, GROα was undetectable (< 5 pg ml-1) in the sputum of 21 out of 25 CF patients, with low levels (range 144-825 pg ml-(1)) in the remainder, and median levels of GROα in CF plasma (33 pg ml-1, n = 24) were not significantly different from controls (34 pg ml-1, n = 25). Lung function [forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC)] was significantly poorer in atopic CF compared to non-atopic CF patients (P < 0.02), but sputum levels of GROα, IL-8 and LTB4 were not different between the subgroups. Our results suggest that unlike LTB4 and IL-8, GROα does not contribute to neutrophilic inflammation in the CF lung, and other factors must determine the impaired lung function observed in atopic CF patients. These results may have important implications in the development of chemokine receptor antagonists as novel anti-inflammatory agents in CF. (C) 2000 HARCOURT PUBLISHERS LTD.

This record has no associated files available for download.

More information

Published date: February 2000
Keywords: Atopy, Chemokine, Cystic fibrosis, GROα

Identifiers

Local EPrints ID: 455310
URI: http://eprints.soton.ac.uk/id/eprint/455310
ISSN: 0954-6111
PURE UUID: 1fdd31d2-e1c2-4a58-8286-46dfde0682e1
ORCID for A. P. Sampson: ORCID iD orcid.org/0009-0008-9653-8935

Catalogue record

Date deposited: 16 Mar 2022 18:07
Last modified: 18 Mar 2024 02:41

Export record

Altmetrics

Contributors

Author: H. A. Wyatt
Author: A. P. Sampson ORCID iD
Author: I. M. Balfour-Lynn
Author: J. F. Price

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×